Celldex Therapeutics

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Celldex Therapeutics  was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in immuno-oncology.
Company Growth (employees)
Hampton, US
Size (employees)
196 (est)
Celldex Therapeutics is headquartered in Hampton, US

Key People at Celldex Therapeutics

Anthony S. Marucci

Anthony S. Marucci

Founder, President & CEO
Avery W. Catlin

Avery W. Catlin

Tibor Keler

Tibor Keler

Founder, SVP & CSO
Thomas Davis

Thomas Davis

Ronald A. Pepin

Ronald A. Pepin

SVP & Chief Business Officer
Harry H. Penner

Harry H. Penner

Co - Founder

Celldex Therapeutics Office Locations

Celldex Therapeutics has offices in Hampton, Branford, Fall River, Needham
Hampton, US
Needham, US
Fall River, US
Branford, US

Celldex Therapeutics Metrics

Celldex Therapeutics Summary

Market capitalization

$401.7 m

Closing share price

Celldex Therapeutics's current market capitalization is $401.7 m.

Celldex Therapeutics Financials

Celldex Therapeutics's revenue is $5.5 m in FY, 2015 which is a 52.8% increase from the previous period.
FY, 2013FY, 2014FY, 2015


$4.1 m$3.6 m$5.5 m

Revenue growth, %



($81.4 m)($122.4 m)($129.5 m)

Net Income

($81.6 m)($118.1 m)($127.2 m)

Operating cash flow

$144.5 m($141.4 m)$44.1 m

Celldex Therapeutics Market Value History

Celldex Therapeutics Company Life

You may also be interested in